Phase II trial evaluating a docetaxel‐capecitabine combination as treatment for hormone‐refractory prostate cancer

Abstract

The results of the current study demonstrated the high efficacy of the DC combination in patients with HRPC, and the associated good tolerability. This combination offers a new alternative to the docetaxel-estramustine combination. Further randomized trials are warranted.